SCI

10 July 2024

Prevalence of EGFR Mutations in Patients With Resected Stage I-III NSCLC: Results From the EARLY-EGFR Study

(Journal of Thoracic Oncology, IF: 21.0)

  • Ross A. Soo, Thanyanan Reungwetwattana, Herman Andres Perroud, Ullas Batra, Saadettin Kilickap, Luis Fernando Tejado Gallegos, Natalia Donner, Mohamed Elsayed, Reto Huggenberger, Dao Van Tu

  • CORRESPONDENCE TO: ross_soo@nuhs.edu.sg

Background 背景

There is limited literature on the prevalence of EGFR mutations in early-stage non-small cell lung cancer (NSCLC). EARLY-EGFR (NCT04742192), a cross-sectional study, determined the prevalence of EGFR mutations in early-stage NSCLC.

关于早期肺癌患者（NSCLC）中EGFR突变率的文献有限。EARLY-EGFR（NCT04742192），一项横断面研究，确定了EGFR突变在早期NSCLC患者中的比率。

 

Methods 方法

This non-interventional, real-world study enrolled consecutive patients with resected stage IA-IIIB (American Joint Committee on Cancer 8th edition) NSCLC from 14 countries across Asia, Latin America, and Middle East and Africa. The primary endpoint was prevalence of EGFR mutations and secondary endpoints included prevalence of EGFR mutation subtypes and treatment patterns.

这项非介入性、真实世界的研究招募了来自亚洲、拉丁美洲、中东和非洲14个国家的可切除IA-IIIB期（美国癌症联合委员会第8版）NSCLC患者。主要终点是EGFR突变率，次要终点包括EGFR突变亚型比率和治疗模式。

 

Results 后果

Of 601 patients (median [range] age: 62.0 [30.0-86.0] years) enrolled, 52.7% were females and 64.2% were non-smokers. The majority had stage IA-IB NSCLC (64.1%) and adenocarcinoma histology (98.7%). Overall prevalence of EGFR mutations was 51.0%; majority reported exon-19 deletions (48.5%) followed by exon-21 L858R mutations (34.0%). Women had a higher EGFR mutation rate than men (64.0% versus 36.4%). Compared with no EGFR mutations, patients with EGFR mutations were more likely to be non-smokers (35.1% versus 60.9%) and have stage I NSCLC compared to stage II and III NSCLC (54.8% versus 47.3% and 35.6%). Systemic adjuvant therapy was planned in 33.8% patients with stage IB to IIIB disease and adjuvant chemoradiotherapy in 6.8% patients. Age ≥60 years, females, and Asians were found to have a significantly (p < 0.05) higher odds of EGFR mutations, while smoking history and stage III disease had lower odds of EGFR mutations.

601名入选患者（中位[范围]年龄：62.0[30.0-86.0]岁）中，52.7%为女性，64.2%为非吸烟者。大多数为IA-IB期NSCLC（64.1%）和腺癌（98.7%）。EGFR突变的总比率为51.0%；大多数突变为外显子19缺失突变（48.5%），其次是外显子21 L858R突变（34.0%）。女性的EGFR突变率高于男性（64.0%对36.4%）。与没有EGFR突变的患者相比，有EGFR突变患者更有可能是非吸烟者（35.1%对60.9%），同时与II期和III期NSCLC相比，有EGFR突变患者更有可能是I期NSCLC（54.8%对47.3%和35.6%）。总共有33.8%的IB至IIIB期患者进行全身辅助治疗，对6.8%的患者进行辅助放化疗。年龄≥60岁、女性和亚洲人的EGFR突变几率显著较高（p<0.05），而有吸烟史和III期疾病的患者EGFR变异几率较低。

 

Conclusion 结论

The EARLY-EGFR study provides an overview of EGFR mutations and subtype prevalence in patients with early-stage NSCLC. The study highlights the limited adherence to treatment guidelines suggesting an unmet need for improved adjuvant therapy.

EARLY-EGFR研究概述了早期NSCLC患者的EGFR突变率和各亚型比率。该研究强调了对治疗指南的有限遵守，这表明对改进辅助治疗的需求尚未得到满足。